93 related articles for article (PubMed ID: 2457380)
1. Amplification of bleomycin-mediated degradation of DNA by polyamines.
Strekowski L; Mokrosz M; Mokrosz JL; Strekowska A; Allison SA; Wilson WD
Anticancer Drug Des; 1988 Aug; 3(2):79-89. PubMed ID: 2457380
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis for potentiation of bleomycin-mediated degradation of DNA by polyamines. Experimental and molecular mechanical studies.
Strekowski L; Harden DB; Wydra RL; Stewart KD; Wilson WD
J Mol Recognit; 1989 Dec; 2(4):158-66. PubMed ID: 2484026
[TBL] [Abstract][Full Text] [Related]
3. Chemical synthesis of radiolabeled bleomycin A2 and its binding to DNA.
Roy SN; Orr GA; Brewer CF; Horwitz SB
Cancer Res; 1981 Nov; 41(11 Pt 1):4471-7. PubMed ID: 6171340
[TBL] [Abstract][Full Text] [Related]
4. [Mechanism of action of bleomycin at the molecular level].
Takita T
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2659-65. PubMed ID: 6210059
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis for bleomycin amplification: conformational and stereoelectronic effects in unfused amplifiers.
Strekowski L; Mokrosz JL; Tanious FA; Watson RA; Harden D; Mokrosz M; Edwards WD; Wilson WD
J Med Chem; 1988 Jun; 31(6):1231-40. PubMed ID: 2453673
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effects of flavonoids and ascorbate on enhancement in DNA degradation induced by a bleomycin-Fe complex.
Sugihara N; Kaneko A; Furuno K
Free Radic Res; 2005 Mar; 39(3):237-44. PubMed ID: 15788228
[TBL] [Abstract][Full Text] [Related]
7. A systematic approach toward the analysis of drug-DNA interactions using Raman spectroscopy: the binding of metal-free bleomycins A(2) and B(2) to calf thymus DNA.
Rajani C; Kincaid JR; Petering DH
Biopolymers; 1999; 52(3):110-28. PubMed ID: 11169380
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of bleomycin-resistant phenotypes of human cell sublines and circumvention of bleomycin resistance by liblomycin.
Lazo JS; Braun ID; Labaree DC; Schisselbauer JC; Meandzija B; Newman RA; Kennedy KA
Cancer Res; 1989 Jan; 49(1):185-90. PubMed ID: 2461797
[TBL] [Abstract][Full Text] [Related]
9. Lidocaine potentiation of bleomycin A2 cytotoxicity and DNA strand breakage in L1210 and human A-253 cells.
Lazo JS; Braun ID; Meandzija B; Kennedy KA; Pham ET; Smaldone LF
Cancer Res; 1985 May; 45(5):2103-9. PubMed ID: 2580616
[TBL] [Abstract][Full Text] [Related]
10. A non-classical intercalation model for a bleomycin amplifier.
Strekowski L; Wilson WD; Mokrosz JL; Strekowska A; Koziol AE; Palenik GJ
Anticancer Drug Des; 1988 Mar; 2(4):387-98. PubMed ID: 2452646
[TBL] [Abstract][Full Text] [Related]
11. Influence of ethidium bromide on hyperthermic modification of bleomycin-DNA interaction.
Nasir Z; Chapman IV
Radiat Res; 1985 Jun; 102(3):295-9. PubMed ID: 2416002
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, characterization and studies on DNA-binding of a new Cu(II) complex with N1,N8-bis(l-methyl-4-nitropyrrole-2-carbonyl)triethylenetetramine.
Zhou CY; Zhao J; Wu YB; Yin CX; Pin Y
J Inorg Biochem; 2007 Jan; 101(1):10-8. PubMed ID: 17010441
[TBL] [Abstract][Full Text] [Related]
13. The presence of two modes of binding to calf thymus DNA by metal-free bleomycin: a low frequency Raman study.
Rajani C; Kincaid JR; Petering DH
Biopolymers; 1999; 52(3):129-46. PubMed ID: 11169381
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, biological activity and DNA interaction of anilinoacridine and bithiazole peptide derivatives related to the anti-tumor drugs m-AMSA and bleomycin.
Morier-Teissier E; Bailly C; Bernier JL; Houssin R; Helbecque N; Catteau JP; Colson P; Houssier C; Hénichart JP
Anticancer Drug Des; 1989 Jun; 4(1):37-52. PubMed ID: 2474298
[TBL] [Abstract][Full Text] [Related]
15. Amplification of bleomycin-mediated degradation of DNA.
Strekowski L; Strekowska A; Watson RA; Tanious FA; Nguyen LT; Wilson WD
J Med Chem; 1987 Aug; 30(8):1415-20. PubMed ID: 2441055
[TBL] [Abstract][Full Text] [Related]
16. Effects of DNA superhelical changes induced by ethidium bromide on the DNA-degrading activity of two antitumor antibiotics, bleomycin and phleomycin.
Huang CH; Mirabelli CK; Mong S; Crooke ST
Cancer Res; 1983 Jun; 43(6):2849-56. PubMed ID: 6189587
[TBL] [Abstract][Full Text] [Related]
17. Role of carbohydrate moiety of bleomycin-A2 in caspase-3 activation and internucleosomal chromatin fragmentation in apoptosis of laryngeal carcinoma cells.
Brahim S; Abid K; Kenani A
Cell Biol Int; 2008 Feb; 32(2):171-7. PubMed ID: 17950632
[TBL] [Abstract][Full Text] [Related]
18. Chelating, DNA-binding and DNA-cleaving properties of a synthetic model for bleomycin.
Kenani A; Lohez M; Houssin R; Helbecque N; Bernier JL; Lemay P; Hénichart JP
Anticancer Drug Des; 1987 Aug; 2(1):47-59. PubMed ID: 2452643
[TBL] [Abstract][Full Text] [Related]
19. NMR study of the effects of some bleomycin C-termini on the structure of a DNA hairpin with the 5'-GC-3' binding site.
Lehmann TE; Murray SA; Ingersoll AD; Reilly TM; Follett SE; Macartney KE; Harpster MH
J Biol Inorg Chem; 2017 Jan; 22(1):121-136. PubMed ID: 27858165
[TBL] [Abstract][Full Text] [Related]
20. NMR studies of the paramagnetic complex Fe(II)-bleomycin.
Lehmann TE; Ming LJ; Rosen ME; Que L
Biochemistry; 1997 Mar; 36(10):2807-16. PubMed ID: 9062108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
